{"title":"肥胖症的药物治疗。现状和新疗法","authors":"","doi":"10.1016/j.aprim.2024.103074","DOIUrl":null,"url":null,"abstract":"<div><p>The high incidence of obesity in our environment, the progressive and recurrent nature of this disease makes it necessary to know and use all the possibilities of prevention and treatment.</p><p>When a person suffers from obesity we must offer a treatment plan with specific objectives that will include healthy eating, physical activity and, if necessary, treatment with medication or even surgery.</p><p>At present in Spain, there are 3 medications available:</p><ul><li><span>•</span><span><p>Orlistat, with low efficacy and little use.</p></span></li><li><span>•</span><span><p>Liraglutide and semaglutide, both based on incretins and capable of improving obesity, diabetes and other obesity-related conditions. The high potency and safety of these drugs has revolutionized the pharmacological treatment of obesity.</p></span></li></ul><p>New molecules will soon be marketed that will expand the treatment possibilities, which will also be reviewed in this article.</p></div>","PeriodicalId":55435,"journal":{"name":"Atencion Primaria","volume":null,"pages":null},"PeriodicalIF":1.8000,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0212656724002166/pdfft?md5=9526f025bd1998b96e023e999e5e9899&pid=1-s2.0-S0212656724002166-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Tratamiento farmacológico de la obesidad. Situación actual y nuevos tratamientos\",\"authors\":\"\",\"doi\":\"10.1016/j.aprim.2024.103074\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>The high incidence of obesity in our environment, the progressive and recurrent nature of this disease makes it necessary to know and use all the possibilities of prevention and treatment.</p><p>When a person suffers from obesity we must offer a treatment plan with specific objectives that will include healthy eating, physical activity and, if necessary, treatment with medication or even surgery.</p><p>At present in Spain, there are 3 medications available:</p><ul><li><span>•</span><span><p>Orlistat, with low efficacy and little use.</p></span></li><li><span>•</span><span><p>Liraglutide and semaglutide, both based on incretins and capable of improving obesity, diabetes and other obesity-related conditions. The high potency and safety of these drugs has revolutionized the pharmacological treatment of obesity.</p></span></li></ul><p>New molecules will soon be marketed that will expand the treatment possibilities, which will also be reviewed in this article.</p></div>\",\"PeriodicalId\":55435,\"journal\":{\"name\":\"Atencion Primaria\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2024-09-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S0212656724002166/pdfft?md5=9526f025bd1998b96e023e999e5e9899&pid=1-s2.0-S0212656724002166-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Atencion Primaria\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0212656724002166\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Atencion Primaria","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0212656724002166","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
Tratamiento farmacológico de la obesidad. Situación actual y nuevos tratamientos
The high incidence of obesity in our environment, the progressive and recurrent nature of this disease makes it necessary to know and use all the possibilities of prevention and treatment.
When a person suffers from obesity we must offer a treatment plan with specific objectives that will include healthy eating, physical activity and, if necessary, treatment with medication or even surgery.
At present in Spain, there are 3 medications available:
•
Orlistat, with low efficacy and little use.
•
Liraglutide and semaglutide, both based on incretins and capable of improving obesity, diabetes and other obesity-related conditions. The high potency and safety of these drugs has revolutionized the pharmacological treatment of obesity.
New molecules will soon be marketed that will expand the treatment possibilities, which will also be reviewed in this article.
期刊介绍：
Atención Primaria es una revista que publica trabajos de investigación relativos al ámbito de la atención primaria de salud. Desde el punto de vista conceptual, Atención Primaria asume el nuevo modelo de atención primaria de salud, orientado no sólo a la curación de la enfermedad, sino también a su prevención y a la promoción de la salud, tanto en el plano individual como en el de la familia y la comunidad. En estos nuevos aspectos que definen el modelo de atención primaria de salud es en los que se centran los trabajos de investigación que publica Atención Primaria, la primera revista de originales española creada para recoger y difundir la producción científica realizada desde los centros de atención primaria de salud sobre cuestiones como protocolización de la asistencia, programas de prevención, seguimiento y control de pacientes crónicos, organización y gestión de la asistencia primaria, entre otros.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
